WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) Wednesday reported fourth-quarter net loss of $37.5 million or $0.33 per share, compared to $22.6 million or $0.24 per share last year.
On average, analysts polled by Thomson Reuters expected loss of $0.48 per share for the quarter. Analysts' estimates typically exclude one-time items.
Revenues for the quarter fell to $15.8 million from $45.3 million last year, mainly due to the completion of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.
Wall Street analysts on a consensus estimated revenues of $12.66 million for the quarter.
Copyright RTT News/dpa-AFX
© 2012 AFX News
